Is It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials?

IF 10 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2024-10-15 DOI:10.1158/1078-0432.CCR-24-1628

Brian A Van Tine, Sasha Haarberg

引用次数: 0

Abstract

Epithelioid hemangioendothelioma is an ultra-rare cancer driven by YAP-CAMTA1 fusion. Based on the link of the fusion to the MEK pathway, SARC33 was performed. It is a phase 2 trial examining trametinib that missed its primary objective by RECIST but demonstrated patient-reported outcome benefits in improved pain. See related article by Schuetze et al., p. 4584.

查看原文本刊更多论文

现在是时候拒绝将 RECIST 作为罕见肿瘤试验的主要终点了吗？

上皮样血管内皮细胞瘤（EHE）是一种由 YAP-CAMTA1 融合驱动的超罕见癌症。基于该融合与 MEK 通路之间的联系，SARC33 试验应运而生。这是一项检查曲美替尼的 2 期试验，该试验未达到 RECIST 的主要目标，但患者报告的结果显示疼痛有所改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.